Get All Access for FREE

Market News & Research,
Fundamental Data,
Live Transcripts & Audio,
AlphaGraphics,

and a whole lot more…

{{::item.ticker}} • {{::item.company_name}} No Results

Get All Access for FREE

Market News & Research,
Fundamental Data,
Live Transcripts & Audio,
AlphaGraphics,

and a whole lot more…

News & Research
Portfolio
Discover
Groups
$BLUE {{ '2017-06-05T16:32:59+0000' | timeago}} • Announcement

$BLUE and $CELG said updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-BCMA CAR T cell therapy, in 18 patients with relapsed/refractory multiple myeloma will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

$SGEN {{ '2017-12-11T16:30:10+0000' | timeago}} • Announcement

$SGEN and $BMY highlighted updated interim results from an ongoing phase 1/2 clinical trial evaluating the combination of Adcetris (brentuximab vedotin) and Opdivo (nivolumab) in relapsed or refractory classical Hodgkin lymphoma (HL).

$CELG {{ '2017-12-11T13:33:44+0000' | timeago}} • Announcement

$CELG and its partner $BLUE announce results of Phase I study of bb2121, a therapy that is jointly developed by both the companies for treating blood cancer. Of the 18 patients enrolled for this trial, 56% achieved complete response and only one patient (6%) didn't respond to the treatment.

$CELG {{ '2017-11-16T14:30:32+0000' | timeago}} • Announcement

$CELG and its partner $BLUE reported that FDA granted Breakthrough Therapy Designation, which will expedite the review of the plasma cell cancer treating therapy. This was based on the preliminary data from the ongoing phase 1 study of the therapy. In March 2013, Celgene and Bluebird Bio entered into a strategic alliance in the field of oncology.

$RGEN {{ '2017-11-07T15:02:00+0000' | timeago}} • Announcement

$RGEN extended a long-term supply agreement with Purolite Life Sciences for the manufacture of Protein A ligands at Repligen’s facilities in Waltham, MA and Lund, Sweden. $RGEN will supply Protein A ligands to Purolite through November 2022, with an option for renewal through 2025.

$TECH {{ '2017-10-31T15:32:14+0000' | timeago}} • Announcement

$TECH has declared a quarterly dividend of $0.32 per share on its common stock. The dividend is payable on November 24, 2017, to shareholders of record on November 10, 2017.

$ISRG {{ '2017-10-19T21:40:26+0000' | timeago}} • Announcement

Worldwide da Vinci procedures grew approx. 15% in 3Q17 as $ISRG shipped 169 da Vinci Surgical Systems during the quarter. With $TRXC already in its sight, Intuitive Surgical will also be eyeing $MDT with much more concern as Medtronic is set to roll out its surgical robot system next year.

$ISRG {{ '2017-10-19T21:22:14+0000' | timeago}} • Announcement

Amidst concern over an emerging competition for its da Vinci Surgical Systems, $ISRG posted its 3Q17 results where revenue increased 18% and profit grew 41%. Recently, the US FDA has shown the green light for $TRXC to market its Senhance Surgical Robotic System, the first system since 2010 to compete head-to-head against $ISRG's da Vinci system.

$SGMO {{ '2017-10-02T16:06:18+0000' | timeago}} • Announcement

$SGMO and $BIVV said the FDA has accepted the Investigational New Drug (IND) application for ST-400, a gene-edited cell therapy candidate for people with transfusion-dependent beta-thalassemia. $SGMO expects to open several clinical sites across the United States and begin enrolling patients in 1H18.

$SGMO {{ '2017-10-02T16:05:15+0000' | timeago}} • Announcement

$SGMO and $BIVV said the FDA has accepted the Investigational New Drug (IND) application for ST-400, a gene-edited cell therapy candidate for people with transfusion-dependent beta-thalassemia. This is as part of exclusive worldwide collaboration to develop and commercialize gene-edited cell therapies for beta-thalassemia and sickle cell disease.

$RGEN {{ '2017-06-23T12:45:15+0000' | timeago}} • Announcement

$RGEN entered into a definitive merger agreement with privately-held Spectrum, Inc. for about $359MM, comprised of $120MM in cash and 6.2MM shares of Repligen stock. The transaction is expected to be completed during 3Q17.

$SGEN {{ '2017-06-15T12:21:22+0000' | timeago}} • Announcement

Pharma firms $SGEN and $BMY presented an interim analysis from the phase 1/2 clinical trial of  lymphoma drugs Adcetris and Opdivo in relapsed or refractory classical Hodgkin lymphoma, at the International Conference on Malignant Lymphoma in Switzerland. The drugs have not been approved, in combination, for the condition or for other indications.

$BLUE {{ '2017-06-05T16:32:59+0000' | timeago}} • Announcement

$BLUE and $CELG said updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-BCMA CAR T cell therapy, in 18 patients with relapsed/refractory multiple myeloma will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

$SGMO {{ '2017-05-11T12:04:01+0000' | timeago}} • Announcement

$SGMO said it is eligible to receive potential milestone payments of up to $475MM, including up to $300MM for the development and commercialization of SB-525 and up to $175MM for additional Hemophilia A gene therapy product candidates that may be developed under the collaboration with $PFE.

$SGMO {{ '2017-05-11T12:03:12+0000' | timeago}} • Announcement

$SGMO said it will be responsible for conducting the SB-525 Phase 1/2 clinical study and certain manufacturing activities. $PFE will be operationally and financially responsible for subsequent research, development, manufacturing and commercialization activities for SB-525 and additional products, if any.

$SGMO {{ '2017-05-11T12:02:25+0000' | timeago}} • Announcement

$SGMO and $PFE announced an exclusive, global collaboration and license agreement for the development and commercialization of gene therapy programs for Hemophilia A, including SB-525, one of $SGMO's four lead product candidates, which $SGMO expects will enter the clinic this quarter. $SGMO will receive a $70MM upfront payment from $PFE.

$AMAG {{ '2017-01-10T13:22:36+0000' | timeago}} • Announcement

$AMAG and $PTN entered into an agreement for exclusive North American rights to develop and commercialize Rekynda. $AMAG will also pay $PTN tiered royalties on net sales ranging from high single-digit to low double-digit percentages. $AMAG expects the transaction to close in 1Q17.

$AMAG {{ '2017-01-10T13:21:11+0000' | timeago}} • Announcement

$AMAG said the expected filing date in the U.S. for a new drug application for Rekynda is in early 2018, with expected approval and launch by early 2019. $AMAG will pay to $PTN $60MM of upfront consideration, up to $80MM contingent upon achieving certain regulatory milestones and up to $300MM contingent upon meeting certain sales milestones.

$AMAG {{ '2017-01-10T13:18:43+0000' | timeago}} • Announcement

$AMAG and $PTN entered into an agreement for exclusive North American rights to develop and commercialize Rekynda (bremelanotide), an investigational product designed for on-demand treatment of hypoactive sexual desire disorder in pre-menopausal women, that has successfully completed two Phase 3 trials.

$RGEN {{ '2016-12-15T12:52:20+0000' | timeago}} • Announcement

$RGEN acquired TangenX Technology Corporation through an all cash transaction of $39MM. $RGEN expects sales of TangenX products to achieve double-digit growth and contribute $7-7.5MM in revenue for 2017. This acquisition is expected to be accretive on both a GAAP EPS and adjusted EPS basis in 2017.

$TECH {{ '2016-10-31T14:59:36+0000' | timeago}} • Webcast

In FY17, $TECH expects overall organic growth to be similar, if not slightly ahead of FY16. The company expects 2Q17 Diagnostics revenue to be relatively flat to the prior year. Adjusted operating margin is expected to improve in 2H17, as Advanced Cell Diagnostics' revenue continues to ramp, producing more volume leverage for the Biotech segment.

Recent Transcripts
RGEN | Earnings
February 22nd 2018, 1:30pm
SYN | Earnings
February 22nd 2018, 1:30pm
SGMO | Earnings
February 22nd 2018, 1:00pm
TXMD | Earnings
February 20th 2018, 9:30pm
AlphaGraphics you may like
Related Feed
Recent Transcripts
RGEN | Earnings
February 22nd 2018, 1:30pm
SYN | Earnings
February 22nd 2018, 1:30pm
SGMO | Earnings
February 22nd 2018, 1:00pm
TXMD | Earnings
February 20th 2018, 9:30pm
AlphaGraphics you may like